Sanofi SA (SNY)
30 Sep 2016
* Sanofi appoints Alan Main to executive committee and executive vice president, consumer healthcare Source text for Eikon: Further company coverage: (Reporting By Dominique Vidalon)
(The following statement was released by the rating agency) MILAN/LONDON, September 27 (Fitch) Fitch Ratings has affirmed L'Oreal SA's (L'Oreal) Short-Term Issuer Default Rating (IDR) and commercial paper (CP) programme at 'F1+'. The agency has also affirmed L'Oreal USA Inc's CP programme, guaranteed by L'Oreal, at 'F1+'. The ratings continue to reflect the company's strong market position and product portfolio as well as its robust geographical diversification. Also, L'Oreal continues to d
Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum.
* The United States Biomedical Advanced Research and Development Authority (BARDA) agrees to fund the manufacture of an inactivated Zika vaccine for phase II development by Sanofi and its vaccines global business unit Sanofi Pasteur
French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.
Sept 26 French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.
* Sanofi and Regeneron announce dupilumab biologics license application accepted for priority review by U.S. FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Files suit in U.S. To defend paten rights on Lantus and Lantus Solostar
New Mexico Attorney General Hector Balderas has sued Bristol-Myers Squibb Co and Sanofi SA's U.S. arm for overstating the effectiveness of and concealing the risks of their blood thinner Plavix.
Sept 15 Teva Pharmaceutical Industries Ltd said on Thursday it was collaborating with Intel Corp to develop a wearable technology platform to track the progression of disease in patients with Huntington's, a fatal degenerative disorder.
|Abbott Laboratories (ABT.N)||$42.25||+0.81|
|AstraZeneca plc (AZN.L)||5,013.00p||-13.00|
|Bristol-Myers Squibb Co (BMY.N)||$54.24||+0.37|
|Bristol-Myers Squibb Co (BMYMP.PK)||$985.00||--|
|Eli Lilly and Co (LLY.N)||$80.60||+0.86|
|GlaxoSmithKline plc (GSK.L)||1,642.50p||-5.00|
|Merck & Co., Inc. (MRK.N)||$62.53||+0.62|
|Novartis AG (NOVN.S)||CHF76.50||-0.75|
|Novo Nordisk A/S (NOVOb.CO)||kr.275.40||-4.60|
|Roche Holding Ltd. (ROG.S)||CHF240.80||-1.00|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (SNY). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Wright Reports
"The Economy Matters" Report for SNYNF: the economy's impact on SNYNF's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider : MacroRisk Analytics/EconomicInvestor
Sanofi-Aventis - Finlabo Research Equity Report: Fundamental and Technical Analysis and 6 months performance forecast
Provider : Finlabo SIM Spa
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.